Our company engages in the research and development, manufacturing, and sales of diagnostic test kits, primarily focused on in vitro diagnostic (IVD) products. In the field of infectious diseases, we provide rapid diagnostic kits for tropical infectious diseases such as dengue fever. In the pre-symptomatic healthcare field, we offer testing solutions—including genetic testing and microbiological testing—for individual and corporate sales, as well as for medical and research institutions. In addition, we collaborate not only within Japan but also with overseas bases and partners, including those in Thailand, and have established a product development and supply system that complies with regulatory requirements in each country.
株式会社ビズジーン（所在地：大阪府茨木市、代表取締役：開發 邦宏）は、認知症リスクに備えるセルフケア習慣をサポートするため、自宅でできる遺伝子検査キット「APOE認知症リスク遺伝子検査キット」を開発しま...
見える化技術で人々の健康をサポートする株式会社ビズジーン(所在地：大阪府茨木市、代表取締役：開發 邦宏)が開発・販売する母乳アルコールチェッカー「ミルクリア」が、2025年7月11日発行の子育て情報誌『クル...
見える化技術で人々の健康をサポートする株式会社ビズジーン(所在地：大阪府茨木市、代表取締役：開發 邦宏)が開発・販売する母乳アルコールチェッカー「ミルクリア」が、2025年7月10日発行の子育て情報誌『WIRE...
株式会社ビズジーン（本社：大阪府茨木市、代表取締役：開發 邦宏）は、2025年6月25日（水）～27日（金）にインテックス大阪で開催された国際医療・ヘルスケア見本市「Japan Health 2025」に出展し、当社が展開す...
遺伝子の「見える化」技術で人々の健康をサポートする株式会社ビズジーン（所在地：大阪府茨木市、代表取締役：開發 邦宏）は、フェムケア専門サロン膣ラボ 「ブーケ」（運営：株式会社WellSideMeeting、所在地：...
大阪大学産業科学研究所発のベンチャー企業、株式会社ビズジーン（事業所：大阪府茨木市美穂ヶ丘、代表取締役：開發 邦宏）は、2025年6月10日（火）から16日（月）まで開催される大阪・関西万博「大阪ヘルスケア...
[画像: https://prtimes.jp/i/54718/12/resize/d54718-12-7815d619440443706053-1.png ] 株式会社ビズジーン(所在地：大阪府茨木市、代表取締役：開發 邦宏)は、インフルエンザウイルスを不活化し、ダイレクトPCR...
[画像1: https://prtimes.jp/i/54718/11/resize/d54718-11-1e4ea474f17dd3b36305-0.jpg ] 「見える化」技術で人々の健康をサポートする株式会社ビズジーン(所在地：大阪府茨木市、代表取締役：開發 邦宏)は、大学...
[画像: https://prtimes.jp/i/54718/9/resize/d54718-9-36fc291603b01d696058-1.png ] 2025年1月中旬よりAmazonで先行販売健康リスクの「見える化」技術で人々の健康をサポートする株式会社ビズジーン(所在地：大...
[画像1: https://prtimes.jp/i/54718/10/resize/d54718-10-edf55a9189f89084c8a1-0.png ] 株式会社ビズジーン(代表:開發邦宏 本社:大阪府茨木市)は、女性の膣内の菌バランスとデリケートゾーンの悩みの関連性調査...
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.
Our company is a R&D driven biotechnology firm specializing in therapeutic and diagnostic seeds for pancreatic cancer. We are developing antibodies that target pancreatic cancer stem cells and products utilizing unique antibodies derived from pancreatic cancer patients. Dedicated to bringing early diagnostic tools and effective treatments for pancreatic cancer to patients as quickly as possible, our goal is to ensure that our drug seeds and innovative technologies make a significant contribution to the treatment and early detection of pancreatic cancer.
Tellme's original business was operating hair salons. Over years of observing changes in their clientele, and as a service for customers who could no longer visit the salon due to illness or aging, the company developed a technology to assess the risk of glycation (a measure of aging) through hair analysis. This technology is currently being promoted as a diabetes screening technology. After being featured at the World Expo, it gained significant attention from overseas countries and institutions for its ability to assess risk without the need for blood sampling. In Japan, the technology is also seen as contributing to behavioral change among the segment of the population indifferent to their own health (kenko mukanshinsō) within local municipalities. Tellme is now pursuing the commercialization of this service as a means of optimizing social security costs.
A startup leveraging its proprietary language processing technology, SATOMI®, to support the automatic generation of medical records and referral letters. By streamlining information use in clinical settings, it promotes regional collaboration and medical DX, contributing to the development of a sustainable healthcare system.
